Children born with so-called “bubble boy” disease have the best chance of survival if they undergo a hematopoietic stem cell transplant as soon after birth as possible, according to a detailed analysis of 10 years of outcome data by researchers at the Harvard-affiliated Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
Researchers say the findings support expanding newborn screening for severe combined immune deficiency (SCID), a disorder that leaves affected infants so vulnerable to infection that most die within the first year of life if untreated.
The study, published today in the New England Journal of Medicine, analyzed data on 240 children
Kim and Jay Case with their dog, Shiloh, at Citizen's Lake Campground in Monmouth on Wednesday morning. Kim won her battle with cancer because of an adult stem cell transplant
When Kim Case was diagnosed with a rare form of cancer, doctors told her she had little chance of survival.
Months later when she was recovering from the disease, they changed their tune.
“The doctors called me their miracle patient,” Case said.
Case, who lives in Gaston, Ore. with her husband, Jay — who’s originally from Monmouth — was diagnosed in August 2004 with a rare form of cancer called NK T-cell
Image via Wikipedia
Transplanting stem cells from one’s own bone marrow (autologous stem cell transplants) improves the symptoms of muscular sclerosis (MS), and in some cases the neurological disease actually regressed. These are the encouraging results obtained from a small study performed on 21 remittent MS patients by a group from the Northwestern University School of Medicine in Chicago and published in Lancet Neurology. “All of the patients,” said the neurologists, “witnessed an improvement in their conditions three years after the stem cell transplants were performed. Of these, 81pct benefited from visible progress, measured in terms of
Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. EP2366775B1, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy”, by the European Patent Office. This patent addresses use of adherent stromal cells from placenta or adipose tissue, expanded according to Pluristem’s methods of three dimensional culturing, for treating conditions that may benefit from facilitation of hematopoietic stem cell engraftment.
As described in the patent, Pluristem’s therapeutic cells are designed to promote the success of hematopoietic stem cell transplantation, which is used to treat
Adult Stem Cell Research Shows that Diabetes Type 1 Can Be Helped
In a Stem Cell research study that is being published today in the Journal of American Medical Association (JAMA), Adult Stem Cells have been used to help patients with Diabetes Type 1.
20 of 23 Patients Helped With Their Own Adult Stem Cells